With an approved treatment in commercial stages and new drug candidates generating clinical trial results, this biotech has ...

An updated edition of the Feb. 20, 2026, article. Genomics involves a thorough study of genomes (an organism’s complete set of deoxyribonucleic acid or DNA). It involves understanding how genes ...

CRISPR Therapeutics (NASDAQ: CRSP) is a pioneering biotech company, but it isn't yet a profitable one. That's why its shares ...

However, there is one key reason the stock could still deliver outstanding returns over the long run: Its pipeline could help ...

Crispr Therapeutics Ag (NASDAQ:CRSP) is one of the Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Biotech company Crispr Therapeutics Ag (NASDAQ:CRSP) shares are up 16% over the past 12 months.

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the stocks that could 10x over the next 10 years. Piper Sandler boosted its ...

CRISPR recently raised nearly $600 million through a private offering, which weighed down its share price. The company has an approved therapy in Casgevy, but its business remains deeply unprofitable.

Crispr Therapeutics AG looks set for 2026 revenue inflection as Casgevy ramps; strong efficacy, undervalued shares, robust ...